In-hospital Diabetes Management With Flash Glucose Monitoring (isCGM) - the INDIGO Study, Part A

University of Aarhus13 enrolled

Overview

The aim of the study is to investigate the applicability of a Flash glucose monitoring sensor (Freestyle Libre, isCGM) for in-hospital glucose monitoring in patients with diabetes requiring nutritional therapy (tube feeding or parenteral feeding).

All patients who meet study criteria will be invited to participate in the study. All patients included in the study will be followed by a trained clinical diabetes specialist and a trained study nurse (study personnel) for glucose management during their hospitalization. All patients included in the study will receive a Freestyle Libre isCGM. The patients will be randomized to control (blinded isCGM glucose values to patient and study personnel and POC (point-of-care) plasma glucose will be used for adjusting diabetes treatment) or intervention (isCGM blood glucose values will be used to aid with glucose management during the hospitalization). The study personnel will work with the patient's care team.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

SINGLE

Enrollment

Conditions

Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus Diabetes Mellitus

Interventions

isCGM groupOTHER

As previously described

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Expected length of hospital stay of at least 48 hours * Diagnosed with diabetes * Literate in Danish * Nutritional therapy using tube feeding or parenteral nutritional therapy * Admission to Department of Gastrointestinal Surgery or Department of Heart-, Lung-, and Vascular surgery, both at Aarhus University Hospital, Denmark. Exclusion Criteria: * Pregnancy * Patient unable to provide informed consent * Patient unable to use mobile phone for reading isCGM sensor * Known allergy to adhesives * Anticipated MRI during the hospital admission * Patients using CGM prior to hospital admission

Locations (1)

Aarhus university hospital

Aarhus, Denmark

Outcomes

Primary Outcomes

Glucose time in range (3,9-10 mmol/l) (% pr day)

Glucose time in range (3,9-10 mmol/l) when diabetes treatment is adjusted using isCGM compared with standard care using POC plasma glucose monitoring (PG) (% pr day)

Time frame: 2-14 days

Secondary Outcomes

Mean glucose (mmol/l) isCGM versus POC PG

Mean glucose (mmol/l) when diabetes treatment is adjusted using isCGM compared with standard care using POC plasma glucose monitoring (PG)

Time frame: 2-14 days

Glycemic variability; coefficient of variation (CV) (in %)

CV when diabetes treatment is adjusted using isCGM compared with standard care using POC plasma glucose monitoring (PG)

Time frame: 2-14 days

Glycemic variability; standard deviation (SD)

SD when diabetes treatment is adjusted using isCGM compared with standard care using POC plasma glucose monitoring (PG)

Time frame: 2-14 days

Time in hypoglycemia (<3 mmol/L) (%)

Time in hypoglycemia (%) when diabetes treatment is adjusted using isCGM compared with standard care using POC plasma glucose monitoring (PG)

Time frame: 2-14 days

Time in hypoglycemia (<3,9 mmol/l) (%)

Time in hypoglycemia (%) when diabetes treatment is adjusted using isCGM compared with standard care using POC plasma glucose monitoring (PG)

Time frame: 2-14 days

Number of events with hypoglycemia (<3,9 mmol/l) (%)

Number of events with hypoglycemia per day (\<3,9 mmol/L for \>15 minutes) when diabetes treatment is adjusted using isCGM compared with standard care using POC plasma glucose monitoring (PG)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.